Patents by Inventor Frederick C. Lahser

Frederick C. Lahser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
    Patent number: 9198907
    Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: December 1, 2015
    Assignee: PTC Therapeutics, Inc.
    Inventors: Frederick C. Lahser, Zhengxian Gu
  • HCV inhibitor and therapeutic agent combinations
    Patent number: 8841302
    Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: September 23, 2014
    Assignee: PTC Therapeutics, Inc.
    Inventors: Frederick C. Lahser, Zhengxian Gu
  • COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT
    Publication number: 20120087893
    Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
    Type: Application
    Filed: April 5, 2010
    Publication date: April 12, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Frederick C. Lahser, Zhengxian Gu
  • HCV Inhibitor and Therapeutic Agent Combinations
    Publication number: 20120070412
    Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 22, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Frederick C. Lahser, Zhengxian Gu
  • COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV IRES INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO
    Publication number: 20090220457
    Abstract: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of: (a) at least one HCV IRES inhibitor; and (b) at least one HCV protease inhibitor; and optionally (c) at least one other therapeutic agent; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in a subject in need thereof.
    Type: Application
    Filed: February 23, 2007
    Publication date: September 3, 2009
    Inventors: Frederick C. Lahser, Gary Mitchell Karp
  • Continuous non-radioactive polymerase assay
    Publication number: 20040142322
    Abstract: This invention provides a sensitive method for detecting RNA-dependent polymerase activity and for characterizing inhibitors of these enzymes, particularly NS5B of HCV and RT of HIV. The invention further provides methods wherein the elongation of RNA is measured in real time through the continuous detection of light generated from a reaction cascade involving a coupled enzyme system based on firefly luciferase.
    Type: Application
    Filed: October 7, 2003
    Publication date: July 22, 2004
    Applicant: Schering Corporation
    Inventors: Bruce A. Malcolm, Frederick C. Lahser